Selina Chen-Kiang, Ph.D. is professor of pathology, Immunology and microbial pathogenesis at Weill Cornell Medical College.  She has been dedicated to translating fundamental discoveries into innovative therapies that address unmet needs in blood cancers and benefit patients.  With the generous support of an MCL-RI grant from LLS, her team has implemented a ground-breaking strategy that both stops cancer cells from dividing and sensitizes them to killing by partner drugs in clinical trials of mantle cell lymphoma (MCL) with promising results. By following each patient longitudinally using advanced genomic methods, her team has discovered new drug resistant markers and developed strategies to overcome drug resistance.  Ongoing effort is focused on further enhancing the durability and depth of targeted therapy as well as immunotherapy by harnessing the novel cancer-immune cell cross talks they have uncovered in MCL patients, with the goal of finding a cure for MCL and other lymphomas.